home · filing · 0001193125-25-002863
8-K filed January 7, 2025, 6:59 PM ET
ticker OACC
CIK 0002029769
leadership
confidence high
sentiment neutral
materiality 0.30
Oaktree Acquisition Corp III board changes: Frank resigns, Kumar chairman, Pardesi appointed director
Oaktree Acquisition Corp. III Life Sciences
John Frank resigned from the board effective Jan 6, 2025, not due to any disagreement with the company.
Aman Kumar, an existing director, was appointed as the new chairman of the board.
CEO Zaid Pardesi was appointed as a Class III director, term expiring at third annual shareholder meeting.
Pardesi and Kumar have material interests in the Sponsor Oaktree Acquisition Holdings III LS, as previously disclosed in the IPO prospectus.
No arrangements or family relationships exist between Pardesi and other directors or executive officers.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-01-06
Filed January 7, 2025, 6:59 PM ET
On January 6, 2025, John Frank resigned from the board of directors (the “Board”) of Oaktree Acquisition Corp. III Life Sciences (the “Company”).
Effective 2025-01-06
Filed January 7, 2025, 6:59 PM ET
the Board appointed (i) Aman Kumar, currently a director of the Company, as the new chairman of the Board
Effective 2025-01-06
Filed January 7, 2025, 6:59 PM ET
and (ii) Zaid Pardesi, the Company’s Chief Executive Officer, as a director of the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
John Frank resigned as director at Oaktree Acquisition Corp. III Life Sciences.
Action resigned
Role director
Exact text from the filing
On January 6, 2025, John Frank resigned from the board of directors (the “Board”) of Oaktree Acquisition Corp. III Life Sciences (the “Company”).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Aman Kumar was appointed as chairman of the board at Oaktree Acquisition Corp. III Life Sciences.
Action appointed
Role chairman of the board
Exact text from the filing
the Board appointed (i) Aman Kumar, currently a director of the Company, as the new chairman of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Zaid Pardesi was appointed as director at Oaktree Acquisition Corp. III Life Sciences.
Action appointed
Role director
Exact text from the filing
and (ii) Zaid Pardesi, the Company’s Chief Executive Officer, as a director of the Company.
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-25-002863
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.